Andrew M. Abbott

Principal

Andrew Abbott is an economist with broad experience providing financial, economic, and econometric analysis in connection with high-stakes litigation in the areas of antitrust and consumer fraud. Mr. Abbott has extensive experience advising clients in all aspects of litigation consulting including market research, big data and document analytics, the development of econometric and statistical models used to measure antitrust impact and damages, and the preparation of expert testimony. Mr. Abbott is well-adept at developing and implementing comprehensive analyses to address multifaceted issues related to allegations of horizontal price-fixing, monopolization, supply restrictions, market allocation, and bid rigging. His work focuses primarily on healthcare and agricultural markets.

Mr. Abbott specializes in analyzing complex pharmaceutical and healthcare markets at the direct and indirect purchaser levels. He is well versed in the pharmaceutical distribution system and the inherent complexities of analyzing injury and damages incurred by payors resulting from anticompetitive hospital mergers, as well as unlawful pay-for-delay and product hopping schemes. Mr. Abbott has developed sophisticated methodologies to analyze antitrust injury, unjust enrichment, and class-wide damages that account for the unique characteristics of the healthcare market including:

  • Formulary Placement
  • Benefit Design
  • Medicare Part-D
  • Medicaid
  • Cost-Sharing
  • Rebates and Price Adjustments
Selected Consulting Experience

  • In Re: Namenda Indirect Purchaser Antitrust Litigation. In a class action involving branded and generic Namenda tablets purchased by third-party payors, managed analyses related to damages and in support of class certification and merits.
  • In Re: Zetia (Ezetimibe) Antitrust Litigation. In a class action antitrust matter involving branded and generic Zetia tablets, managed analyses related to damages and in support of class certification and merits.
  • The Hospital Authority of Metropolitan Government of Nashville and Davidson County, Tennessee, et al. v. Momenta Pharmaceuticals, Inc., et al. In a class action antitrust matter involving an injectable anticoagulant, managed analyses related to damages and in support of class certification and merits.
  • First Impressions Salon, Inc., et al., v. National Milk Producers Federation, et al. In a class action matter involving butter and cheese prices, assisted in developing an econometric analysis to measure the impact of a herd reduction program on butter and cheese prices.
  • In Re: Lamictal Direct Purchaser Antitrust Litigation. In a class action antitrust matter involving branded and generic Lamictal tablets, a drug used to treat epilepsy and bi-polar disorder, managed analyses related to damages and in support of class certification and merits.
  • In Re: Liquid Aluminum Sulfate Indirect Purchaser Antitrust Litigation. In a class action antitrust matter involving bid rigging for water treatment chemicals, assisted counsel with a damages calculation for settlement.
  • In Re: Namenda Direct Purchaser Antitrust Litigation. In a class action antitrust matter involving branded and generic Namenda tablets, assisted in developing a model to measure classwide damages.
  • In Re: Evanston Northwestern Healthcare Antitrust Litigation. In a class action antitrust matter involving a hospital merger, assisted in developing a model to demonstrate classwide injury and calculated damages to third-party payors and patients.

Do you need industry experts for your next case?
Contact Us